Sugi Predict

Sugi Predict / Compounds / SCHEMBL9468935

SCHEMBL9468935

SCHEMBL9468935

CC(C)(C)OC(=O)N[C@@H](CCC(N)=O)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CTSK P43235 6/20 0.35
▸ CTSS P25774 4/20 0.35
▸ REN P00797 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.34
▸ ITGB3 P05106 1/20 0.34
▸ ITGA2B P08514 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ BCHE P06276 2/20 0.34
▸ ACHE P22303 2/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ NFKB2 Q00653 1/20 0.34
▸ RELA Q04206 1/20 0.34
▸ KLK7 P49862 1/20 0.34
▸ EPHX2 P34913 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17911923 0.89 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL14708937 0.89 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL3749003 0.89 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL30557797 0.89 CTSS (0.38) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL13265369 0.89 CYP1A2 (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL30678053 0.88 HTT (0.39) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL3750972 0.88 SRC (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL12712551 0.86 CTSK (0.48) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL7065349 0.86 CTSK (0.48) CYP1A2CYP2C9CYP2C19HTTCTSK
SCHEMBL23771861 0.85 CTSL (0.40) CYP1A2CYP2C9CYP2C19HTTCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612420-B2 Arginase inhibitors and methods of use thereof MOLECURE S.A. (PL) 2026-04-28 — — US disclosed
EP-4267590-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF ONCOARENDI THERAPEUTICS S.A. (PL) 2023-11-01 — — EP disclosed
WO-2022137156-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF Oncoarendi Therapeutics S.A. (PL) 2022-06-30 — — WO disclosed
US-20220204530-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF MOLECURE S.A. (PL) 2022-06-30 — — US disclosed
EP-2084154-B1 AMINOACYL PRODRUG DERIVATIVES AND MEDICAMENTS FOR TREATMENT OF THROMBOEMBOLIC DISORDERS BAYER IP GMBH (DE) 2012-11-21 — — EP disclosed
US-5189046-A Antiinflammatory agents, anticonvulsants NOVA PHARMACEUTICAL CORPORATION (US) 1993-02-23 — — US disclosed
WO-1992003415-A1 PROTEIN KINASE C MODULATORS NOVA PHARMACEUTICAL CORPORATION (US) 1992-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220204530-A1 ARGINASE INHIBITORS AND METHODS OF USE THEREOF ARG1, ARG2, PRMT1 CYP1A2 429/4885CYP2C9 1053/4885CYP2C19 1148/4885
US-12612420-B2 Arginase inhibitors and methods of use thereof ARG1, ARG2, ARGLU1 CYP1A2 2718/4885CYP2C9 1861/4885CYP2C19 2588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback